Second Quarter (Interim Period) Consolidated Results for the Fiscal Year Ending December 2026
Carna Biosciences,Inc. (consolidated)
BTK inhibitor docirbrutinib (AS-1763, hematologic cancers including chronic lymphocytic leukemia (CLL)); BTK inhibitor sofnobrutinib (AS-0871, immune and inflammatory diseases); CDC7 inhibitor monzosertib (AS-0141, solid tumors and hematologic cancers including acute myeloid leukemia (AML)); and the drug discovery support business
Losses recorded in connection with substantial upfront investment, primarily in clinical trial-related expenses for docirbrutinib and monzosertib. Cash on hand at the end of the interim consolidated accounting period may not be sufficient to fund the research and development required from 1 July 2026 onward.
Interim net loss attributable to owners of the parent: ¥1,039 million (¥1,039,782 thousand); negative net assets: ¥407 million (¥407,840 thousand; excess liabilities); non-operating expenses: ¥56 million (¥56,048 thousand); extraordinary loss: ¥32 million (¥32,489 thousand)
Interim consolidated accounting period for the fiscal year ending December 2026 (1 January 2026 to 30 June 2026)
No change to the consolidated earnings forecast for the fiscal year ending December 2026. The full-year forecast is revenue of ¥720 million, an operating loss of ¥2,028 million, an ordinary loss of ¥2,053 million, and a net loss attributable to owners of the parent of ¥2,090 million.
The Company will promote clinical trials for its development-stage pipeline and seek to secure upfront license fees and milestone payments through the execution of license agreements. It will expand revenue from the drug discovery support business and consider measures to strengthen its financial foundation, including financing. The Company aims to out-license docirbrutinib during 2026 and plans to out-license monzosertib after confirming its efficacy in a Phase 1b trial.
| Item | Details |
|---|---|
| Event name | Second Quarter (Interim Period) Consolidated Results for the Fiscal Year Ending December 2026 |
| Date of occurrence | 30 June 2026 (end of the interim consolidated accounting period; the Company determined that an event existed that could raise substantial doubt about the going concern assumption) |
| Date recognized / date notice received | 30 June 2026 (determined as of the end of the interim consolidated accounting period) |
| Subject Entity | Carna Biosciences,Inc. (consolidated) |
| Target Locations / Products | BTK inhibitor docirbrutinib (AS-1763, hematologic cancers including chronic lymphocytic leukemia (CLL)); BTK inhibitor sofnobrutinib (AS-0871, immune and inflammatory diseases); CDC7 inhibitor monzosertib (AS-0141, solid tumors and hematologic cancers including acute myeloid leukemia (AML)); and the drug discovery support business |
| Cause | Losses recorded in connection with substantial upfront investment, primarily in clinical trial-related expenses for docirbrutinib and monzosertib. Cash on hand at the end of the interim consolidated accounting period may not be sufficient to fund the research and development required from 1 July 2026 onward. |
| Amount of Impact on Business Performance | Interim net loss attributable to owners of the parent: ¥1,039 million (¥1,039,782 thousand); negative net assets: ¥407 million (¥407,840 thousand; excess liabilities); non-operating expenses: ¥56 million (¥56,048 thousand); extraordinary loss: ¥32 million (¥32,489 thousand) |
| Accounting period in which recognized | Interim consolidated accounting period for the fiscal year ending December 2026 (1 January 2026 to 30 June 2026) |
| Impact on Earnings Forecast | No change to the consolidated earnings forecast for the fiscal year ending December 2026. The full-year forecast is revenue of ¥720 million, an operating loss of ¥2,028 million, an ordinary loss of ¥2,053 million, and a net loss attributable to owners of the parent of ¥2,090 million. |
| Outlook | The Company will promote clinical trials for its development-stage pipeline and seek to secure upfront license fees and milestone payments through the execution of license agreements. It will expand revenue from the drug discovery support business and consider measures to strengthen its financial foundation, including financing. The Company aims to out-license docirbrutinib during 2026 and plans to out-license monzosertib after confirming its efficacy in a Phase 1b trial. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explained that it has recorded losses due to substantial upfront investment, primarily in clinical trial-related expenses for docirbrutinib and monzosertib, and that cash on hand at the end of the interim period may not be sufficient to fund the research and development required from 1 July 2026 onward. Accordingly, the Company determined that a material uncertainty existed regarding the going concern assumption.